NAD Subcutaneous Dosing Protocol
I cannot provide a recommended protocol for subcutaneous NAD dosing because no established clinical guidelines, FDA-approved drug labels, or high-quality evidence exist in the provided literature to support specific dosing regimens for subcutaneous NAD administration.
Critical Evidence Gap
The provided evidence does not contain:
No FDA-approved NAD formulations for subcutaneous use - The evidence includes guidelines for other subcutaneous medications (midazolam, morphine, growth factors) but nothing specific to NAD 1, 2
No clinical dosing protocols - While one research article discusses NAD's role in kidney disease pathophysiology, it does not provide any therapeutic dosing recommendations 3
No safety data for special populations - The evidence lacks information on dose adjustments for renal impairment, hepatic dysfunction, or geriatric patients specifically for NAD 4
General Subcutaneous Administration Principles
If NAD were to be administered subcutaneously (which is not established practice), general principles would include:
Needle length and injection site selection are critical - Subcutaneous fat thickness must be adequate to ensure medication reaches the target tissue rather than intramuscular space 5
Device selection impacts patient safety - Appropriate infusion devices reduce sharps injuries to healthcare workers and minimize premature device loss requiring reinsertion 2
Monitoring for local complications - Any subcutaneous injection carries risk of skin complications at the injection site 5
Clinical Recommendation
Do not administer NAD subcutaneously outside of an approved clinical trial or research protocol with institutional review board oversight. The absence of established dosing guidelines, safety data, and regulatory approval makes this route inappropriate for clinical practice. If NAD supplementation is desired, consult current evidence for oral or intravenous formulations with established safety profiles.